Stock SPHDF SANTHERA PHARMACEUTICALS HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

News Santhera Pharmaceuticals Holding AG OTC Markets

Equities

SPHDF

CH1276028821

Market Closed - OTC Markets
Other stock markets
 10:53:09 22/02/2024 pm IST 		5-day change 1st Jan Change
11.7 USD +4.00% Intraday chart for Santhera Pharmaceuticals Holding AG -.--% -.--%
19/06 Transcript : Santhera Pharmaceuticals Holding AG - Special Call
18/06 Santhera Secures CHF69 Million Financing for Bond Repayment, Cash Runway Extension MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Transcript : Santhera Pharmaceuticals Holding AG - Special Call
Santhera Secures CHF69 Million Financing for Bond Repayment, Cash Runway Extension
MT
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
AQ
Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow Break-Even
AQ
Santhera Announces Launch of Early Access Program in China for AGAMREE® by its Partner Sperogenix
AQ
Santhera Publishes Agenda for its Annual General Meeting
AQ
Santhera Publishes Annual Report 2023
AQ
Transcript : Santhera Pharmaceuticals Holding AG, 2023 Earnings Call, Apr 25, 2024
Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows
MT
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
AQ
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis
MT
Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China
MT
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA
AQ
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA
CI
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
AQ
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
CI
Santhera's New Study Shows Efficacy, Safety Data for Duchenne Muscular Dystrophy Treatment
MT
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SANN Stock
  4. SPHDF Stock
  5. News Santhera Pharmaceuticals Holding AG